RESvEraTrol in Parkinson's Disease (RESET)
NCT07592767
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is an exploratory phase 2a study to investigate two doses of resveratrol (JotrolTM) vs placebo in individuals diagnosed with Parkinson's Disease (PD). Participants (n=30) will be randomized 1:1:1 into 3 groups and will receive oral JotrolTM vs placebo. Study drug will be titrated to reach a final maximal dose per group and will be administered orally once daily (QD) for 3 months. The study will primarily evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of JotrolTM.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinson's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 55 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Georgetown University
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- Georgetown University Hospital · Washington D.C., DC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.